FDA Approves Yescarta as a First CAR T-cell Therapy for Initial Treatment of R/R Large B-cell Lymphoma
Until now, existing CAR-T therapies have been reserved for patients with blood cancer who have tried multiple treatments. The FDA has approved Yescarta, a CD19-directed CAR-T therapy developed by Gilead Sciences' Kite Pharma, for the treatment of patients with Large B-cell Lymphoma that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.
Yescarta's approval has put it ahead of Bristol Myers Squibb's rival drug Breyanzi, which is expecting an FDA decision for the same second-line lymphoma indication by June 24. ...
